AXXAM

Screening & Hit-to-Lead

From gene to validated and qualified hits

Leave a Comment / Screening & Hit-to-Lead, Blog /

Science Spyglass From Gene to Validated and Qualified HitsHigh-Throughput Screening at Axxam Despite a constantly expanding repertoire of therapeutic modalities, small molecules continue to account for the majority of new drug approvals and continue to attract attention and investigation, especially with the expansion of the knowledge on different mechanisms of action, including pharmacological chaperones, targeted […]

From gene to validated and qualified hits Read More »

Thermal shift assays for early-stage drug discovery

Leave a Comment / In-vitro Assays, Screening & Hit-to-Lead, Blog /

Science Spyglass Unlocking the Power of Thermal Shift Assays for Early-Stage Drug Discovery Thermal-shift assay (TSA) represents a powerful tool for protein-stability analysis and for discovering and characterizing new protein binders. Understanding protein stability is crucial for drug development, protein engineering, and other biotechnology applications. Among the various methods available for assessing protein stability, TSA

Thermal shift assays for early-stage drug discovery Read More »

shRNA for gene knock down in screening campaigns

Leave a Comment / In-vitro Assays, Screening & Hit-to-Lead, Blog /

Science Spyglass Why is shRNA better than siRNA for gene knock down in screening campaigns? One of the first challenges to face in the drug discovery process, is the generation of reliable in-vitro models that mimic the pathological conditions of the disease being studied. Many diseases are caused by the loss of function of a

shRNA for gene knock down in screening campaigns Read More »

Scroll to Top